Summit Therapeutics (SMMT) Equity Average (2020 - 2025)
Summit Therapeutics' Equity Average history spans 6 years, with the latest figure at $225.9 million for Q3 2025.
- For Q3 2025, Equity Average fell 28.64% year-over-year to $225.9 million; the TTM value through Sep 2025 reached $225.9 million, down 28.64%, while the annual FY2024 figure was $233.2 million, 128.26% up from the prior year.
- Equity Average reached $225.9 million in Q3 2025 per SMMT's latest filing, down from $301.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $413.3 million in Q4 2024 to a low of $57.9 million in Q2 2022.
- Average Equity Average over 5 years is $156.9 million, with a median of $110.9 million recorded in 2021.
- Peak YoY movement for Equity Average: crashed 53.14% in 2024, then soared 501.37% in 2025.
- A 5-year view of Equity Average shows it stood at $92.8 million in 2021, then soared by 40.05% to $130.0 million in 2022, then tumbled by 31.87% to $88.5 million in 2023, then soared by 366.86% to $413.3 million in 2024, then plummeted by 45.36% to $225.9 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Equity Average are $225.9 million (Q3 2025), $301.9 million (Q2 2025), and $366.5 million (Q1 2025).